- |||||||||| Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt
Trial completion date, Trial primary completion date: Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - Mar 8, 2023
P2, N=15, Not yet recruiting,
Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026 Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Sep 2023 --> Dec 2025
- |||||||||| Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt
Trial initiation date, Trial primary completion date: Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - Apr 18, 2022
P2, N=15, Not yet recruiting,
Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Sep 2023 --> Dec 2025 Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Sep 2023
- |||||||||| Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt
Trial completion date, Trial initiation date, Trial primary completion date: Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - Nov 26, 2021
P2, N=15, Not yet recruiting,
Initiation date: Mar 2022 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Sep 2023 Trial completion date: Mar 2024 --> Jun 2024 | Initiation date: Sep 2021 --> Mar 2022 | Trial primary completion date: Sep 2023 --> Mar 2023
|
